{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=13&q=advanced+melanoma",
    "query": {
      "q": "advanced melanoma",
      "condition": "Melanoma",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 832,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=14&q=advanced+melanoma&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=12&q=advanced+melanoma&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T00:41:05.708Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02890368",
      "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Mycosis Fungoides",
        "Melanoma",
        "Merkel-cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Breast Carcinoma",
        "Human Papillomavirus-Related Malignant Neoplasm",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "TTI-621 Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "TTI-621 + PD-1/PD-L1 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "TTI-621 + pegylated interferon-α2a",
          "type": "DRUG"
        },
        {
          "name": "TTI-621 + T-Vec",
          "type": "OTHER"
        },
        {
          "name": "TTI-621 + radiation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2016-09",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 7,
      "location_summary": "Duarte, California • New York, New York • Portland, Oregon + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02890368"
    },
    {
      "nct_id": "NCT06194929",
      "title": "Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Melanoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Avutometinib",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-03-20",
      "completion_date": "2030-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 2,
      "location_summary": "Iowa City, Iowa • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06194929"
    },
    {
      "nct_id": "NCT06940739",
      "title": "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable Melanoma",
        "Metastatic Melanoma",
        "Ocular Melanoma"
      ],
      "interventions": [
        {
          "name": "IOV-3001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Iovance Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 42,
      "start_date": "2025-03-11",
      "completion_date": "2032-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Chapel Hill, North Carolina • Nashville, Tennessee",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06940739"
    },
    {
      "nct_id": "NCT00089219",
      "title": "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "IFA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "6MHP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2003-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-11-20",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089219"
    },
    {
      "nct_id": "NCT07819474",
      "title": "Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tumor Infiltrating Lymphocyte",
        "CD8-PET",
        "Advanced Melanoma"
      ],
      "interventions": [
        {
          "name": "Crefmirlimb",
          "type": "DRUG"
        },
        {
          "name": "PET/CT imaging",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2027-02-18",
      "completion_date": "2030-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07819474"
    },
    {
      "nct_id": "NCT00675727",
      "title": "Safety Study of CADI-05 in Patients With Advanced Stage Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage III or Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "CADI-05",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cadila Pharnmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-06-11",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 1,
      "location_summary": "Allentown, Pennsylvania",
      "locations": [
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675727"
    },
    {
      "nct_id": "NCT03993379",
      "title": "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "CX-072",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytomX Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2019-11-20",
      "completion_date": "2020-05-21",
      "has_results": true,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03993379"
    },
    {
      "nct_id": "NCT03957096",
      "title": "A Safety Study of SGN-CD47M in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Breast Carcinoma",
        "Ovarian Carcinoma",
        "Exocrine Pancreatic Carcinoma",
        "Gastric Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "SGN-CD47M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-07-17",
      "completion_date": "2020-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 5,
      "location_summary": "Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03957096"
    },
    {
      "nct_id": "NCT03329950",
      "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer",
        "Other Solid Tumors",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Mantle Cell Lymphoma",
        "Indolent B-cell Lymphomas",
        "Non-Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Waldenstrom's Disease",
        "Marginal Zone Lymphoma",
        "Mucosa Associated Lymphoid Tissue",
        "Small Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CDX-1140",
          "type": "DRUG"
        },
        {
          "name": "CDX-301",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2017-12-01",
      "completion_date": "2022-09-13",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03329950"
    },
    {
      "nct_id": "NCT06264180",
      "title": "VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Melanoma"
      ],
      "interventions": [
        {
          "name": "Vusolimogene Oderparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab + Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single-agent chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2024-07-11",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-15T00:41:05.708Z",
      "location_count": 50,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06264180"
    }
  ]
}